Abstract:The Rb/E2F network has a critical role in regulating cell cycle progression and cell fate decisions. It is dysfunctional in virtually all human cancers, because of genetic lesions that cause overexpression of activators, inactivation of repressors, or both. Paradoxically, the downstream target of this network, E2F1, is rarely strongly overexpressed in cancer. E2F1 can induce both proliferation and apoptosis but the factors governing these critical cell fate decisions remain unclear. Previous studies have focused on qualitative mechanisms such as differential cofactors, posttranslational modification or state of other signaling pathways as modifiers of the cell fate decisions downstream of E2F1 activation. In contrast, the importance of the expression levels of E2F1 itself in dictating the downstream phenotypes has not been rigorously studied, partly due to the limited resolution of traditional population-level measurements. Here, through single-cell quantitative analysis, we demonstrate that E2F1 expression levels have a critical role in determining the fate of individual cells. Low levels of exogenous E2F1 promote proliferation, moderate levels induce G1, G2 and mitotic cell cycle arrest, and very high levels promote apoptosis. These multiple anti-proliferative mechanisms result in a strong selection pressure leading to rapid elimination of E2F1-overexpressing cells from the population. RNA-sequencing and RT-PCR revealed that low levels of E2F1 are sufficient to induce numerous cell cycle-promoting genes, intermediate levels induce growth arrest genes (i.e., p18, p19 and p27), whereas higher levels are necessary to induce key apoptotic E2F1 targets APAF1, PUMA, HRK and BIM. Finally, treatment of a lung cancer cell line with a proteasome inhibitor, MLN2238, resulted in an E2F1-dependent mitotic arrest and apoptosis, confirming the role of endogenous E2F1 levels in these phenotypes. The strong anti-proliferative activity of moderately overexpressed E2F1 in multiple cancer types suggests that targeting E2F1 for upregulation may represent an attractive therapeutic strategy in cancer.

E2F1 and RNA binding protein QKI comprise a negative feedback in the cell cycle regulation.

E2F1 Promotes Cell Cycle Progression by Stabilizing Spindle Fiber in Colorectal Cancer Cells

SCYL1-BP1 affects cell cycle arrest in human hepatocellular carcinoma cells via Cyclin F and RRM2.

E2F1 Renders Prostate Cancer Cell Resistant to ICAM-1 Mediated Antitumor Immunity by NF-κB Modulation.

YY1 Promotes Colorectal Cancer Proliferation Through the Mir-526B-3p/e2f1 Axis.

E2F1 Transactivates IQGAP3 and Promotes Proliferation of Hepatocellular Carcinoma Cells Through IQGAP3-mediated PKC-alpha Activation.

RNA-binding Protein QKI Regulates Contact Inhibition Via Yes-associate Protein in Ccrcc

Rna-Binding Protein Quaking, A Critical Regulator of Colon Epithelial Differentiation and A Suppressor of Colon Cancer

miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A.

QKI-6 inhibits bladder cancer malignant behaviours through down-regulating E2F3 and NF-κB signalling.

RNA-binding Protein QKI-5 Inhibits the Proliferation of Clear Cell Renal Cell Carcinoma Via Post-Transcriptional Stabilization of RASA1 Mrna

Expression level is a key determinant of E2F1-mediated cell fate

An intermediate Rb–E2F activity state safeguards proliferation commitment

Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F

The clinical significance of p53 and pRb signal pathway in esophageal cancer patients

E2F is required for STAT3-mediated upregulation of cyclin B1 and Cdc2 expressions and contributes to G2-M phase transition.

Zbtb7 suppresses the expression of CDK2 and E2F4 in liver cancer cells: implications for the role of Zbtb7 in cell cycle regulation.

Cyclin K regulates prereplicative complex assembly to promote mammalian cell proliferation

E2F1 Induces KIF26A Transcription and Promotes Cell Cycle Progression via CDK–RB–E2Fs Feedback Loop in Breast Cancer

SUMOylation of Rb Enhances Its Binding with CDK2 and Phosphorylation at Early G1 Phase

E2F1 represses beta-catenin/TCF activity by direct up-regulation of Siah1.